TCM
ABVX

TCG Crossover Management’s Abivax ABVX Stock Holding History

TCG Crossover Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801M Sell
6,007,834
-473,251
-7% -$53.6M 19.24% 1
2026
Q1 		$722M Sell
6,481,085
-630,511
-9% -$74.6M 20.65% 1
2025
Q4 		$959M Hold
7,111,596
– – 31.74% 1
2025
Q3 		$604M Buy
7,111,596
+1,055,000
+17% +$64.7M 29.7% 1
2025
Q2 		$46.3M Hold
6,056,596
– – 5.29% 6
2025
Q1 		$37.9M Hold
6,056,596
– – 5.16% 6
2024
Q4 		$44.3M Hold
6,056,596
– – 4.33% 8
2024
Q3 		$69.8M Hold
6,056,596
– – 5.91% 4
2024
Q2 		$80.1M Buy
6,056,596
+4,956,596
+451% +$70.9M 8.34% 3
2024
Q1 		$15.7M Hold
1,100,000
– – 1.24% 24
2023
Q4 		$11.8M Buy
+1,100,000
New +$11.2M 1.31% 22

Other funds holding ABVX

HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

TCG Crossover Management's ABVX Position: Q2 2026 in Review

TCG Crossover Management reduced its Abivax (ABVX) stake by 7.3% in Q2 2026, selling an estimated $53.6M and leaving 6,007,834 shares worth $801M. The position accounts for 19.24% of the portfolio, ranked #1.

TCG Crossover Management first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $959M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • TCG Crossover Management held 6,007,834 shares of Abivax worth $801M as of Q2 2026.
  • TCG Crossover Management sold 473,251 Abivax shares in Q2 2026, an estimated $53.6M.
  • Abivax made up 19.24% of TCG Crossover Management's portfolio in Q2 2026, its #1 holding.
  • TCG Crossover Management first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • TCG Crossover Management's Abivax position peaked at $959M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.